» Articles » PMID: 15158095

Stromal Cell Protection of B-lineage Acute Lymphoblastic Leukemic Cells During Chemotherapy Requires Active Akt

Overview
Journal Leuk Res
Date 2004 May 26
PMID 15158095
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Several studies document ALL cell response to survival signals from bone marrow stromal cells. The current study suggests a requirement for active Akt in ALL cells for optimal stromal cell protection during chemotherapy. ALL cells expressing dominant negative Akt were not efficiently rescued from Ara-C or etoposide-induced apoptosis by stromal cell co-culture. In addition, inhibition of ALL cell PI-3 kinase activity diminished stromal cells support of tumor cells during treatment. ALL cell lines co-cultured with bone marrow stromal cells during chemotherapy maintained higher levels of phosphorylated Akt protein and reduced PP2A activity when compared to ALL cells treated in medium alone. Chemotherapy-induced PARP and Bcl-2 cleavage was reduced in ALL cells cultured with a stromal cell layer compared to tumor cells exposed to drug in medium alone. However, interaction with stromal cells was not able to efficiently block treatment-induced PARP or Bcl-2 cleavage in leukemic cells with blunted Akt activity. These data suggest a pivotal role for Akt in mediating stromal cell regulation of ALL cell apoptosis.

Citing Articles

The Role of Curcumin in Cancer: A Focus on the PI3K/Akt Pathway.

Zoi V, Kyritsis A, Galani V, Lazari D, Sioka C, Voulgaris S Cancers (Basel). 2024; 16(8).

PMID: 38672636 PMC: 11048628. DOI: 10.3390/cancers16081554.


PI3K Targeting in Non-solid Cancer.

Kim H, Ogana H, Sanchez V, Nichols C, Kim Y Curr Top Microbiol Immunol. 2022; 436:393-407.

PMID: 36243854 PMC: 10075235. DOI: 10.1007/978-3-031-06566-8_17.


Pitavastatin Is Anti-Leukemic in a Bone Marrow Microenvironment Model of B-Lineage Acute Lymphoblastic Leukemia.

Piktel D, Nair R, Rellick S, Geldenhuys W, Martin K, Craig M Cancers (Basel). 2022; 14(11).

PMID: 35681662 PMC: 9179467. DOI: 10.3390/cancers14112681.


and effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia.

Ruan Y, Kim H, Ogana H, Gang E, Li S, Liu H Exp Ther Med. 2021; 23(1):47.

PMID: 34934426 PMC: 8652384. DOI: 10.3892/etm.2021.10969.


Toward Therapeutic Targeting of Bone Marrow Leukemic Niche Protective Signals in B-Cell Acute Lymphoblastic Leukemia.

Delahaye M, Salem K, Pelletier J, Aurrand-Lions M, Mancini S Front Oncol. 2021; 10:606540.

PMID: 33489914 PMC: 7820772. DOI: 10.3389/fonc.2020.606540.